A key reveal from this past year of pandemic response is how timely, accurate and accessible data can inform and guide health system decision-making. Good data, effectively applied, can transform clinical outcomes. The UK’s recent RECOVERY (Randomized Evaluation of COVID-19 Therapies) trial is a case in point: it found that a common steroid drug, dexamethasone, although not effective in all patients, still reduced mortality by one-third for the sickest patients, providing an evidence-based alternative to costly hospitalizations.
Yet the converse is also true: 18 months into the pandemic, little data exists on the impact of non-pharmaceutical interventions against COVID-19, especially among the most vulnerable populations classified by geography, gender, age, race or disability
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?